医疗专业人员

下面列出了当前开展的临床试验。

根据地点、状态和其他条件对此研究列表进行过滤。

1. A Study to Establish a Retinoblastoma Patient Clinical Database and Tissue Repository

   Rochester, Minn.

   The purpose of this study is to systematically and prospectively record accurate and complete data regarding the clinical presentation, treatment, and outcomes of patients diagnosed with RB; collect, bank, preserve, and analyze biomaterials from patients with RB, and to correlate phenotypic data with findings from human biomaterials.

    

2. Circulating Tumor DNA (cTDNA) Based in NGS (Next Generation Sequencing) Assays for Oncology Patients With Solid Tumors

   Rochester, Minn.

   The purpose of this study is to design, develop and assess the performance characteristics of NGS assays using circulating tumor DNA for the detection of mutations associated solid tumors.

   The performance characteristics of these assays for detecting ctDNA mutation in oncology patients will be assessed by comparing the mutation results obtained from these assays to those obtained by orthogonal methods, including tissue-based assays and results from a ctDNA assay by Guardant on blood.

3. A Prospective Ocular Tumor Study

   Rochester, Minn.

   The purpose of this study is to use clinical, imaging, molecular, and epidemiological investigation toward the goal of providing new knowledge about ocular tumors that will be useful in understanding, diagnosing, monitoring, and suggesting new avenues of treatment. This study does not involve experimental treatment of any ocular tumor, but rather observation of tumor natural history or outcomes following standard of care therapy, associated systemic and ocular conditions, and basic research investigations to better understand tumor biomarkers and pathophysiology.

4. A Study To Evaluate EAA181 To Treat Newly-diagnosed Multiple Myeloma

   Rochester, Minn., La Crosse, Wis.

   The primary purpose of this study is to determine if bortezomib, daratumumab, lenalidomide and dexamethasone (Btz-DRd) consolidation followed by daratumumab and lenalidomide (DR) maintenance after standard induction therapy with daratumumab, lenalidomide and dexamethasone (DRd) results in superior overall survival compared to DRd consolidation followed by DR maintenance, in MRD positive patients.

5. ROF2181

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   Currently, only a few international institutions use CIRT to treat pelvic bone sarcomas. Accordingly, data evaluating the potential differences in oncological outcomes, toxicities, and functional outcomes between CIRT and the more readily accessible local therapies of surgery and PT is scarce. For this reason, we propose conducting a prospective comparative effectiveness study evaluating functional outcomes, toxicities, and local control in patients with pelvic bone sarcomas treated with surgery, PT, and CIRT.

6. A Bio-bank for Patients with Inflammatory Bowel Disease Associated Neoplasia

   Rochester, Minn.

   The purpose of this study is to collect blood and stool samples to validate and improve the performance of stool and blood DNA markers for inflammatory bowel disease and colorectal neoplasia critical to the long-term goal of improving effectiveness of neoplasia detection in patients using non-invasive biomarkers to assist colonoscopy and radiographic screening. 

7. Blood And Urine Identification Of Methylated DNA Markers In Invasive Bladder Carcinoma

   Rochester, Minn.

   The purpose of this study is to, in tissue, discover and validate DNA methylation markers (MDMs) for detection of invasive urothelial carcinoma of the bladder. In blood, to assess the accuracy of candidate MDMs from above for detection of invasive urothelial carcinoma of the bladder. In urine, to explore the accuracy of candidate MDMs from above for detection of invasive urothelial carcinoma of the bladder.  Diagnostic accuracy on urine can be compared with that on plasma using paired samples.

8. A Feasibility Study To Evaluate The Safety Of The TheraSphere Glioblastoma (GBM) Device In Patients With Recurrent GBM

   Jacksonville, Fla.

   The purpose of this study is to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent glioblastoma (GBM).

9. A Study Of CGM In GBM

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to compare standard glucose monitoring versus continuous glucose monitoring (CGM) with endocrinology-guided intervention in newly diagnosed glioblastoma (GBM) patients receiving standard-of-care therapy.

10. AZD0486 As Monotherapy In Participants With Relapsed/Refractory (R/R) B-cell NHL

    Rochester, Minn.

    This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of AZD0486 monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for DLBCL.